1970 MS, University of Vermont, Physiology & Biophysics
1977 PhD, University of Vermont, Cell Biology
Epithelial cell differentiation
Chemical and Physical Carcinogenesis and Cell Injury
Oxygen free radicals
Molecular Biology of Antioxidant Enzymes in lung
1995 - Present Director, Environmental Pathology Program, University of Vermont
1995 - 1998 Program Leader, Cell Signaling and Growth Control Research Program, Vermont Cancer Center1992 - Present Professor, Department of Pathology, University of Vermont
1989 - Present Adjunct Faculty Member, In Vitro Cell Biology and Biotechnology Program, State University of New York, Plattsburgh, NY1984 - 1992 Associate Professor, Department of Pathology, University of Vermont
1984 - 1988 Chair, Cell and Molecular Biology Program, University of Vermont1980 - 1983 Assistant Professor, Department of Pathology, University of Vermont
1978 - 1980 Research Assistant Professor, Department of Pathology, University of Vermont1975 - 1977 Research Associate, Department of Pathology, University of Vermont
1973 - 1974 Research Assistant, Department of Pathology, University of Vermont1970 - 1973 Research Assistant, Institute of Environmental Medicine, New York Univ, Sterling Forest, NY
1968 - 1970 Research Assistant, Department of Obstetrics & Gynecology, University of Vermont1968 - 1970 Graduate Student, Physiology and Biophysics, University of Vermont
2011 University Distinguished Professor Award, University of Vermont
2010 University of Vermont College of Medicine Medical Alumni Association Graduate Alumni Award
2008 Wagner Award, International Mesothelioma Interest Group Meeting, Amsterdam, NL, for Historic Contributions to Mesothelioma Research
2007 American Thoracic Society Career Achievement Recognition Award for Scientific Accomplishments
2004 Alumni Achievement Award, University of Vermont College of Medicine
1981-1982 University of Vermont Medical Scholar Award for "outstanding and sustained research and scholarly contributions to both the academic discipline and the life of the University of Vermont"
2011 Shukla A, Hillegass JM, Macpherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 2011 Sep 1;129(5):1075-86. doi: 10.1002/ijc.25763.
2011 Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):76-121.2011 Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, Macpherson MB, Butnor KJ, Vacek PC, McGee SP, Clark JC, Steele C, Mossman BT. Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am J Pathol. 2011 May;178(5):1975-85.
2011 Shukla A, Barrett TF, Macpherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT. An ERK2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. Am J Respir Cell Mol Biol. 2011 Mar 31.2010 Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 2010 Dec 15;9:314.
For a complete list of Brooke Mossman's publications, please visit PubMed.